These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12559513)

  • 41. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
    Barkhof F; van Waesberghe JH; Filippi M; Yousry T; Miller DH; Hahn D; Thompson AJ; Kappos L; Brex P; Pozzilli C; Polman CH;
    Brain; 2001 Jul; 124(Pt 7):1396-402. PubMed ID: 11408334
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
    Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
    Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus.
    Horwitz DA; Gray JD; Behrendsen SC; Kubin M; Rengaraju M; Ohtsuka K; Trinchieri G
    Arthritis Rheum; 1998 May; 41(5):838-44. PubMed ID: 9588735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4.
    Rudwaleit M; Yin Z; Siegert S; Grolms M; Radbruch A; Braun J; Sieper J
    Ann Rheum Dis; 2000 Apr; 59(4):311-4. PubMed ID: 10733482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.
    Lin X; Tench CR; Turner B; Blumhardt LD; Constantinescu CS
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1090-4. PubMed ID: 12876240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study.
    Bermel RA; Innus MD; Tjoa CW; Bakshi R
    Neuroreport; 2003 Mar; 14(3):335-9. PubMed ID: 12634479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disability in progressive MS is associated with T2 lesion changes.
    Ammitzbøll C; Dyrby TB; Lyksborg M; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Garde E; Sørensen PS; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2018 Feb; 20():73-77. PubMed ID: 29324249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Failure of catecholamines to shift T-cell cytokine responses toward a Th2 profile in patients with rheumatoid arthritis.
    Wahle M; Hanefeld G; Brunn S; Straub RH; Wagner U; Krause A; Häntzschel H; Baerwald CG
    Arthritis Res Ther; 2006; 8(5):R138. PubMed ID: 16889669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL; Wynn DR; Alam MS; Valdes J
    Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ADC measurements in various patterns of multiple sclerosis lesions.
    Phuttharak W; Galassi W; Laopaiboon V; Laopaiboon M; Hesselink JR
    J Med Assoc Thai; 2006 Feb; 89(2):196-204. PubMed ID: 16579006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens.
    Dearman RJ; Moussavi A; Kemeny DM; Kimber I
    Immunology; 1996 Dec; 89(4):502-10. PubMed ID: 9014813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study.
    Bakshi R; Benedict RH; Bermel RA; Caruthers SD; Puli SR; Tjoa CW; Fabiano AJ; Jacobs L
    Arch Neurol; 2002 Jan; 59(1):62-8. PubMed ID: 11790232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
    Enghard P; Langnickel D; Riemekasten G
    Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?
    Strasser-Fuchs S; Enzinger C; Ropele S; Wallner M; Fazekas F
    Mult Scler; 2008 Mar; 14(2):205-11. PubMed ID: 17986507
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
    Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
    Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis.
    Giugni E; Pozzilli C; Bastianello S; Gasperini C; Paolillo A; Koudriavtseva T; Frontoni M; Farina D; Bozzao L
    Mult Scler; 1997 Aug; 3(4):221-5. PubMed ID: 9372503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon-γ and tumor necrosis factor-α promote the ability of human placenta-derived mesenchymal stromal cells to express programmed death ligand-2 and induce the differentiation of CD4(+)interleukin-10(+) and CD8(+)interleukin-10(+)Treg subsets.
    Li H; Wang W; Wang G; Hou Y; Xu F; Liu R; Wang F; Xue J; Hu T; Luan X
    Cytotherapy; 2015 Nov; 17(11):1560-71. PubMed ID: 26432559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.
    Piancone F; Saresella M; Marventano I; La Rosa F; Zoppis M; Agostini S; Longhi R; Caputo D; Mendozzi L; Rovaris M; Clerici M
    Sci Rep; 2016 Jul; 6():29699. PubMed ID: 27412504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.